subscribeSubscribe
Alnylam Announces Publication of Results from Phase 3 Study of Patisiran

Alnylam Announces Publication of Results from Phase 3 Study of Patisiran
BUSINESSWIRE
25 Oct 2023
Share Share
FDA Blocks Alnylam’s Bid to Expand Onpattro Label

FDA Blocks Alnylam’s Bid to Expand Onpattro Label
BIOSPACE
10 Oct 2023
Share Share
Alnylam Stock Trading Halted Today

Alnylam Stock Trading Halted Today
BUSINESSWIRE
13 Sep 2023
Share Share
FDA questions efficacy of Alnylam`s patisiran in disabling ATTR-CM

FDA questions efficacy of Alnylam`s patisiran in disabling ATTR-CM
Zachary Brennan ENDPTS
12 Sep 2023
Share Share
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO
BUSINESSWIRE
30 Jun 2023
Share Share
Alnylam Announces FDA Acceptance of Supplemental NDA for ONPATTRO

Alnylam Announces FDA Acceptance of Supplemental NDA for ONPATTRO
BUSINESSWIRE
21 Feb 2023
Share Share
Alnylam to face FDA Adcomm for Onpattro`s ATTR-CM bid

Alnylam to face FDA Adcomm for Onpattro`s ATTR-CM bid
Angus Liu FIERCE PHARMA
21 Feb 2023
Share Share
Alnylam Submits sNDA to U.S. FDA for ONPATTRO for Cardiomyopathy

Alnylam Submits sNDA to U.S. FDA for ONPATTRO for Cardiomyopathy
BUSINESSWIRE
08 Dec 2022
Share Share
Alnylam`s new Onpattro data raise fresh doubts: analyst

Alnylam`s new Onpattro data raise fresh doubts: analyst
Angus Liu FIERCEPHARMA
03 Oct 2022
Share Share
Alnylam to Present Data from the APOLLO-B PIII Study of Patisiran in Patients

Alnylam to Present Data from the APOLLO-B PIII Study of Patisiran in Patients
BUSINESSWIRE
13 Sep 2022
Share Share